TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9037326

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (Group 2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Normotensive smokers (Group 3)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Normotensive nonsmokers with hypercholesterolemia (Group 4)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Normotensive smokers with hypercholesterolemia (Group 5)
Number of subjects: 57
Study: 1742814

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 MAC and 1.0 MAC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Halothane (0.5 MAC and 1.0 MAC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane and Halothane
Number of subjects: 30
Study: 6754064

Group type: EXPERIMENTAL
Intervention: Involved fields
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mantle
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Extended fields
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Involved fields followed by 6 cycles of MOPP
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mantle (for upper torso presentations)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Involved fields alone (for upper torso presentations)
Number of subjects: 95
Study: 31221169

Group type: EXPERIMENTAL
Intervention: Clinical scenarios describing seniors
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Clinical scenarios describing women
Number of subjects: 586
Study: 28875447

Group type: EXPERIMENTAL
Intervention: Deliberation groups
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 444
Study: 26735540

Group type: EXPERIMENTAL
Intervention: Novum group (biomarker-assisted decision-making using MR-proADM levels)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard group (decision-making solely based on clinical assessment)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Novum group
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 398
Study: 23607331

Group type: EXPERIMENTAL
Intervention: Task-focusing strategy (10 minute instruction to cope with stress by posing two questions)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Task-focusing strategy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 20146611

Group type: EXPERIMENTAL
Intervention: Speeded response condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nonspeeded response condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Overall memory accuracy
Number of subjects: 2
Study: 19433387

Group type: EXPERIMENTAL
Intervention: Up-front zoledronic acid (ZA; 4 mg intravenously every 6 months)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Up-front zoledronic acid (ZA)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (ZA)
Number of subjects: 301
Study: 16904446

Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (TER) 4 mg daily
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study: 14698800

Group type: EXPERIMENTAL
Intervention: 1 mg buprenorphine per day
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: 3 mg buprenorphine per day
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: 8 mg buprenorphine per day
Number of subjects: 513
Study: 11331256

Group type: EXPERIMENTAL
Intervention: T-wave shock of 10 J in group A (first 45 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: T-wave shock of 15 J in group B (last 35 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inductionless implantations overall
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electrophysiological study at 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Appropriate first shocks for rapid ventricular tachycardia or VF
Number of subjects: 80
Study: 9850404

Group type: EXPERIMENTAL
Intervention: Chloroquine plus chlorpheniramine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 100
Study: 7824150

Group type: EXPERIMENTAL
Intervention: Low-dose nitroglycerin (5-20 micrograms/minute)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose nitroglycerin (80-240 micrograms/minute)
Number of subjects: 58
Study: 3415015

Group type: EXPERIMENTAL
Intervention: N2O (70%) and fentanyl (10 micrograms/kg iv bolus followed by 4 micrograms.kg‐1.h‐1 infusion) with additional warming (humidified respiratory gases, warmed intravenous fluids, and a heating blanket over the legs; n = 5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: N2O (70%) and fentanyl (10 micrograms/kg iv bolus followed by 4 micrograms.kg‐1.h‐1 infusion) with standard temperature management (no special warming measures; n = 10)
Number of subjects: 15
Study: 31303367

Group type: EXPERIMENTAL
Intervention: Traditional Radial Access (TRA)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 205
Study: 30265636

Group type: EXPERIMENTAL
Intervention: Rater training (7‐minute video incorporating frame‐of‐reference training elements)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No training
Number of subjects: 47
Study: 27720659

Group type: EXPERIMENTAL
Intervention: Mouth-exercising device (MED)
Number of subjects: 282

Group type: COMPARATOR
Intervention: No mouth-exercising device (Control)
Number of subjects: 282
Study: 25768796

Group type: EXPERIMENTAL
Intervention: Epilation (repeated plucking of lashes)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1300
Study: 23780477

Group type: EXPERIMENTAL
Intervention: Youth initiated mentoring (YIM)
Number of subjects: 1173
Study: 21091898

Group type: EXPERIMENTAL
Intervention: 0.5 g phenacetin (single oral dose)
Number of subjects: 70
Study: 18208572

Group type: EXPERIMENTAL
Intervention: 125 mg capsule of aprepitant
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80 mg capsule of aprepitant
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16772708

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 12,000 U twice/month for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (nonanemic CRF patients)
Number of subjects: 20
Study: 14634405

Group type: COMPARATOR
Intervention: 5 cc saline
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 2.5 cc 1% lidocaine (bilateral basal injection)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 5 cc 1% lidocaine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 10 cc 1% lidocaine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 10 cc 1% lidocaine (bilateral basal plus apical injections)
Number of subjects: 175
Study: 10952826

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients with elevated glucose levels
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients in NYHA-FC III/IV
Number of subjects: 663

Group type: COMPARATOR
Intervention: Patients with normal glucose and insulin levels
Number of subjects: 663
Study: 8770374

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8448236

Group type: EXPERIMENTAL
Intervention: Relaxation, guided imagery, and biofeedback training
Number of subjects: 13

Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 13
Study: 3945762

Group type: EXPERIMENTAL
Intervention: Iotrol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 49
Study: 31871717

Group type: EXPERIMENTAL
Intervention: Nurse-led patient education
Number of subjects: 0
Study: 30522550

Group type: EXPERIMENTAL
Intervention: Propylthiouracil, Jelfa tablets
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propycil tablets
Number of subjects: 15
Study: 27671540

Group type: EXPERIMENTAL
Intervention: Home Safety (HS) programme
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Home Safety + Home Exercise (HS+HE) programme
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (usual care and social visits)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Home Exercise (HE) programme
Number of subjects: 49
Study: 23984944

Group type: EXPERIMENTAL
Intervention: Negatively arousing emotional events during navigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral or positively arousing emotional events during navigation
Number of subjects: 0
Study: 23635626

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination (Metoclopramide 10 mg + Ondansetron 4 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 21115456

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 h for 5-14 days
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam 1 g every 12 h for 5-14 days
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam
Number of subjects: 1378
Study: 18204830

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 582

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 582
Study: 16580114

Group type: EXPERIMENTAL
Intervention: Nulite F (N)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Alert (A)
Number of subjects: 63
Study: 12728068

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS) in the open arm
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard 7-point BG profiles in the blinded arm
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CGMS monitoring
Number of subjects: 27
Study: 11255651

Group type: EXPERIMENTAL
Intervention: CAPD in diabetic nephropathy patients (group 1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: CAPD in non-diabetic patients (group 2)
Number of subjects: 17
Study: 8973669

Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy (MVAC or MVEC)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Cystectomy only
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (randomized group)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Cystectomy only (randomized group)
Number of subjects: 166
Study: 1434877

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low-dose aspirin (medical treatment)
Number of subjects: 71
Study: 6477250

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of 2% mepivacaine hydrochloride (with hyaluronidase added in 12 patients)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Addition of hyaluronidase
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 49
Study: 30631986

Group type: EXPERIMENTAL
Intervention: Amnion chorion membrane (ACM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DBM) putty
Number of subjects: 22
Study: 30060688

Group type: EXPERIMENTAL
Intervention: Bayesian correspondence criteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized experiment
Number of subjects: 0
Study: 27818376

Group type: EXPERIMENTAL
Intervention: Environmental home-based intervention package (improved solid-fuel stoves, kitchen sinks, solar disinfection of drinking water, hygiene promotion)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Attention control group (early child stimulation programme)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Environmental home-based intervention package
Number of subjects: 503
Study: 24300901

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood drug involvement
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood social cohesion
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Objective neighborhood disorder
Number of subjects: 359
Study: 22405251

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin plus prednisolone (2 mg/kg per day for 15 days after C-reactive protein normalised)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day)
Number of subjects: 248
Study: 21099590

Group type: EXPERIMENTAL
Intervention: C31G
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Nonoxynol-9
Number of subjects: 1565
Study: 18679597

Group type: EXPERIMENTAL
Intervention: Combined treatment group (Jieze No.1 + Azithromycin)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Jieze No.1 alone
Number of subjects: 393

Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 393
Study: 16291411

Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg QD plus Metformin 500 mg TID (G + M)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg QD plus Metformin 500 mg TID (R + M)
Number of subjects: 99
Study: 11977438

Group type: EXPERIMENTAL
Intervention: HIV‐Risk TLFB Interview
Number of subjects: 34

Group type: COMPARATOR
Intervention: 27 sexual behavior frequency questions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diet and nutrition using the TLFB format
Number of subjects: 34
Study: 10424932

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy using tissue plasminogen activator (tPA) at a dose of 0.9 mg/kg body weight.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Streptokinase therapy.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ancrod therapy (STAT study).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (general).
Number of subjects: 100
Study: 7480513

Group type: EXPERIMENTAL
Intervention: Lowered tryptophan levels and ingestion of alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-alcoholic drinks
Number of subjects: 0
Study: 2112180

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (IV STK)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen (IV TPA)
Number of subjects: 19
Study: 1270971

Group type: EXPERIMENTAL
Intervention: Ethanol (133.7 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (orange juice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiments (weighing unsmoked tobacco and counting puffs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol days
Number of subjects: 0
Study: 31919283

Group type: EXPERIMENTAL
Intervention: Project-based research ethics curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31059697

Group type: EXPERIMENTAL
Intervention: AVP (vasopressin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 0
Study: 29173606

Group type: EXPERIMENTAL
Intervention: High ticagrelor loading dose (360 mg)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Conventional ticagrelor loading dose (180 mg)
Number of subjects: 278
Study: 25801488

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 140

Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 140
Study: 23818121

Group type: EXPERIMENTAL
Intervention: D1-P4
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: D1-RV coil
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: P4-RV coil
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: P4-M2
Number of subjects: 21

Group type: COMPARATOR
Intervention: Spontaneous rhythm
Number of subjects: 21
Study: 20522508

Group type: EXPERIMENTAL
Intervention: Gardening
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reading (Control)
Number of subjects: 30
Study: 19196482

Group type: EXPERIMENTAL
Intervention: Beach-based intervention promoting sunless tanning, including sun damage imaging and sun safety recommendations.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Questionnaire only control group.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Beach-based intervention promoting sunless tanning.
Number of subjects: 250
Study: 16495695

Group type: EXPERIMENTAL
Intervention: Percutaneous local ablative therapy (PLAT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 180
Study: 12795812

Group type: EXPERIMENTAL
Intervention: APV600/RTV BID
Number of subjects: 211

Group type: COMPARATOR
Intervention: APV1200 BID
Number of subjects: 211
Study: 10695534

Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium (3.0 (1.2‐6.8) mls/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (Acyanotic subjects)
Number of subjects: 23
Study: 9347370

Group type: EXPERIMENTAL
Intervention: Patient-initiated, pressure-regulated, volume-controlled ventilation (PRVC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV)
Number of subjects: 60
Study: 8248660

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (specific types not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3942665

Group type: EXPERIMENTAL
Intervention: Technique A: I:E ratio 0.43, driving pressure 2.9 bar, no PEEP
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Technique B: I:E ratio 1.0, driving pressure 1.9 bar, no PEEP
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Technique C: I:E ratio 0.43, driving pressure 1.8 bar, PEEP 11 cm H2O
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All techniques (A, B, C)
Number of subjects: 7
Study: 31573387

Group type: EXPERIMENTAL
Intervention: Insoluble yeast β‐glucan (250 mg, 250 mL/day)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Soluble yeast β‐glucan (250 mg, 250 mL/day)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 29361920

Group type: EXPERIMENTAL
Intervention: OA‐CAT Functional Difficulty scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PROMIS® Physical Function CAT
Number of subjects: 0
Study: 27301941

Group type: EXPERIMENTAL
Intervention: 8-week caregiver-mediated exercises program with e-health support
Number of subjects: 63
Study: 25479348

Group type: EXPERIMENTAL
Intervention: Electronic data capture (EDC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Paper-based questionnaire (QNN)
Number of subjects: 150
Study: 22090363

Group type: EXPERIMENTAL
Intervention: Oral losmapimod 7.5 mg twice daily
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol/fluticasone propionate 50 µg/500 µg combination (SFC)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 20384393

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg single oral dose in ESRD patients
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Duloxetine 20-60 mg once or twice daily in phase II/III trials
Number of subjects: 463

Group type: COMPARATOR
Intervention: Duloxetine in ESRD patients
Number of subjects: 463
Study: 18727457

Group type: COMPARATOR
Intervention: 7-day standard triple therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy plus L. reuteri
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy plus probiotic mixture
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 14-day standard triple therapy plus probiotic mixture
Number of subjects: 65
Study: 15999046

Group type: EXPERIMENTAL
Intervention: Steroid group (1 g of methylprednisolone before surgery and 4 mg of dexamethasone every 6 hours for 1 day after surgery)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 12379550

Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.27 ppm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 12
Study: 10636535

Group type: EXPERIMENTAL
Intervention: Tirofiban and enoxaparin (n=26)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Tirofiban and enoxaparin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tirofiban and unfractionated heparin (n=27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tirofiban and unfractionated heparin
Number of subjects: 55
Study: 8943976

Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 626
Study: 1758395

Group type: EXPERIMENTAL
Intervention: DDAVP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DDAVP and Acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study: 7181738

Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 400 mg cholesterol and 0.8 polyunsaturated-to-saturated fat ratio
Number of subjects: 6494

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 6494
Study: 31602471

Group type: EXPERIMENTAL
Intervention: WW + OT (Weight Watchers plus OnTrack)
Number of subjects: 181

Group type: COMPARATOR
Intervention: WW (Weight Watchers)
Number of subjects: 181
Study: 27495968

Group type: EXPERIMENTAL
Intervention: Standard surgery plus standard voice therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Voice Therapy Expulsion
Number of subjects: 150
Study: 25847554

Group type: EXPERIMENTAL
Intervention: Black seeds (1.5g/day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Turmeric (2.4g/day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Combination (900mg Black seeds and 1.5g Turmeric/day)
Number of subjects: 250
Study: 23545664

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 26

Group type: COMPARATOR
Intervention: Olmesartan
Number of subjects: 26
Study: 21443724

Group type: EXPERIMENTAL
Intervention: Repetitive rectal painful distention (RRD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous CRF (100 µg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) ratings
Number of subjects: 27
Study: 19234822

Group type: EXPERIMENTAL
Intervention: 0.3 mg IV ramosetron
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.1 mg oral ramosetron
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 120